Catalog No.
Product Name
Application
Product Information
Citations
-
SIRT1 Modulator
Cannabisin F is a modulator of SIRT1, derived from hempseed lignanamide. It exhibits significant anti-inflammatory and antioxidant properties, making it a valuable candidate for research focused on neurodegenerative diseases. Cannabisin F may influence critical pathways involving SIRT1, NF-κB, and Nrf2, contributing to its potential therapeutic applications. -
Sesquiterpene Compound
β-Curcumene is a sesquiterpene compound known for its potential to activate SIRT1 and inhibit NF-κB pathways. This compound exhibits significant biological activity, making it valuable in research related to metabolic disorders such as type 2 diabetes. Additionally, β-Curcumene's aromatic properties render it useful in the development of flavors, fragrances, and cosmetic applications. -
SIRT1 Activator
SRTCX1002 is a selective activator of the SIRT1 enzyme, functioning primarily through the promotion of p65 deacetylation, which subsequently inhibits NF-κB activity. This compound effectively suppresses inflammatory responses, demonstrated by its ability to inhibit stimuli-induced NF-κB transcriptional activation and reduce LPS-induced TNFα secretion, with IC50 values of 0.71 µM and 7.58 µM, respectively. SRTCX1002 serves as a valuable reagent for research focused on inflammation and related signaling pathways. -
ADRB2 Agonist
Indacaterol acetate is an orally active ultra-long-acting agonist of the β2 adrenergic receptor (ADRB2). It exhibits anti-inflammatory properties by inhibiting NF-κB activity in a β-arrestin2-dependent manner, thereby mitigating lung damage and enhancing lung function in chronic obstructive pulmonary disease (COPD). Additionally, Indacaterol acetate serves as a valuable reagent in cardiovascular disease research. -
Adrenergic Receptor Antagonist
Dicentrine hydrochloride is an adrenergic receptor antagonist known for its anti-inflammatory and anti-cancer properties. It enhances TNF-α-induced apoptosis in A549 lung adenocarcinoma cells by increasing the activities of key apoptotic markers, including caspase-8, -9, -3, and poly(ADP-ribose) polymerase (PARP). Additionally, Dicentrine hydrochloride inhibits TNF-α-induced invasion and migration of A549 cells by downregulating the TAK1, p38, JNK, and Akt signaling pathways, as well as reducing NF-κB and AP-1 transcriptional activities. This compound is valuable for research in cancer biology and therapeutic development. -
MARCKS Inhibitor
BIO-11006 is a specific inhibitor of the MARCKS protein, known for its role in modulating inflammatory responses. This peptide attenuates lipopolysaccharide (LPS)-induced neutrophil influx into lung tissues, suppresses NF-κB activation, and reduces the expression of proinflammatory cytokines such as KC and TNF-α. BIO-11006 has demonstrated efficacy in reversing disease progression in an LPS-induced mouse model of lung injury, making it a valuable tool for research into acute lung injury and acute respiratory distress syndrome (ALI/ARDS). -
NF-κB Inhibitor
Demethyleneberberine chloride is an NF-κB inhibitor that exhibits significant anti-inflammatory properties. This compound has been shown to alleviate colitis in murine models by modulating inflammatory responses through inhibition of the NF-κB pathway and regulation of T helper cell balance. Additionally, Demethyleneberberine chloride acts as an AMPK activator, making it a valuable reagent for research into non-alcoholic fatty liver disease (NAFLD). -
Proteasome Inhibitor
PR-39 is a natural proline- and arginine-rich antibacterial peptide that functions as a noncompetitive, reversible allosteric inhibitor of the proteasome. By binding to the α7 subunit of the proteasome, PR-39 effectively blocks the degradation of NF-κB inhibitor IκBα through the ubiquitin-proteasome pathway. This compound demonstrates key biological activities such as stimulating angiogenesis and inhibiting inflammatory responses, making it a valuable tool for research on myocardial infarction and inflammatory diseases. -
GPR120 Agonist
9-PAHSA is a potent endogenous agonist of the GPR120 receptor, demonstrating an EC50 of 18 μM. This compound effectively inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway, showcasing its anti-inflammatory properties. Additionally, 9-PAHSA promotes adipocyte browning, enhances glucose uptake, and diminishes lipid accumulation, while supporting mitochondrial function in steatotic hepatocytes. It also exhibits neuroprotective effects by modulating the expression of REST and BDNF in the prefrontal cortex of diabetic mice, preventing cognitive deficits and abnormal social behaviors. 9-PAHSA is valuable for research into diabetes-related cognitive impairment, obesity, and non-alcoholic fatty liver disease. -
CXCR2 Receptor Antagonist
AZ10397767 is a selective antagonist of the CXCR2 receptor, exhibiting an IC50 of 1 nM. This compound effectively reduces NF-κB transcriptional activity induced by Oxaliplatin and enhances apoptosis in androgen-independent prostate cancer (AIPC) cells. Additionally, AZ10397767 significantly diminishes neutrophil recruitment to tumors, which may inhibit tumor growth in both in vitro and in vivo models, making it a valuable tool in cancer research. -
apoE-mimetic Peptide
COG112 is an antennapedia-linked apoE-mimetic peptide that targets inflammatory pathways. It effectively attenuates nitric oxide production and inhibits the expression of CXC chemokines such as KC and MIP-2. Additionally, COG112 reduces the nuclear translocation of NF-κB and inhibits the phosphorylation of IκB-α, thereby preventing its degradation. This peptide is valuable for research applications focused on modulating inflammatory responses, particularly in the context of Citrobacter rodentium infection. -
CTH/H2S/NF-κB/EMT Inhibitor
TKL002 is a selective inhibitor targeting the CTH/H2S/NF-κB/EMT signaling pathway, proven to penetrate the blood-brain barrier. It effectively induces G2/M phase cell cycle arrest and apoptosis in glioblastoma cells, simultaneously inhibiting their migration and invasion. This compound upregulates E-cadherin while downregulating N-cadherin and vimentin, making it a valuable tool for investigative studies in glioblastoma research. -
Survivin Inhibitor
MX107 is a selective survivin inhibitor known for its potent efficacy in suppressing the proliferation of triple-negative breast cancer (TNBC) cells. By inducing the degradation of survivin and inhibitor-of-apoptosis proteins (IAPs), MX107 effectively inhibits nuclear factor κB (NF-κB) activation in response to DNA damage. This compound enhances the tumoricidal effects of genotoxic treatments when used in conjunction with chemotherapeutic agents, making it a valuable tool in cancer research and therapy development. -
RIPK2 Inhibitor
CSLP43 is a selective inhibitor of RIPK2, demonstrating an IC50 of 19.9 nM against human RIPK2. By binding to the ATP-binding pocket of RIPK2, CSLP43 disrupts its interaction with the BIR2 domain of XIAP and cIAP1, effectively inhibiting RIPK2 ubiquitination and regulating NOD1- and NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation. This compound is particularly relevant for research investigating Crohn's disease, Blau syndrome, early-onset sarcoidosis, and early-onset inflammatory bowel disease, due to its selectivity for the NOD1/NOD2 signaling pathway without affecting RIPK1 or RIPK3 activity. -
NF-κB Inhibitor/p53 Activator
CBLC100 is an NF-κB inhibitor and a p53 activator that exhibits potent anticancer properties. By targeting FACT, CBLC100 induces cytotoxicity through both p53-dependent apoptotic and non-apoptotic pathways. This compound is particularly relevant for research applications centered on cancers, including fibrosarcoma, making it a valuable tool for studying tumorigenesis and therapeutic responses. -
p53-MDM2 Inhibitor
p53-MDM2-IN-2 is an orally active inhibitor targeting the p53-MDM2 interaction, exhibiting a Ki value of 0.25 μM. This compound demonstrates antitumor activity through the inhibition of the NF-κB signaling pathway. It is valuable in research studies focusing on cancer therapy and elucidating the molecular mechanisms of tumor suppression. -
p53-MDM2 Inhibitor
p53-MDM2-IN-3 is a potent p53-MDM2 inhibitor with a Ki value of 0.25 μM, demonstrating oral bioavailability. This compound exhibits significant antitumor activity through its inhibition of the NF-κB signaling pathway. It serves as a valuable tool for cancer research, particularly in studies focused on targeting the p53-MDM2 interaction and the subsequent effects on tumor proliferation and survival. -
Herbicide/Microtubule inhibitor
Ethalfluralin is a dinitroaniline herbicide that functions as a microtubule inhibitor. By disrupting intranuclear spindle formation, Ethalfluralin effectively obstructs nuclear division and cytokinesis in parasites. This compound also enhances phosphorylation of NF-κB and P38 MAPK while inhibiting the PI3K/AKT signaling pathway, leading to impaired mitochondrial functionality, apoptosis, endoplasmic reticulum stress, autophagy, and increased reactive oxygen species (ROS) production. Ethalfluralin is particularly relevant for research applications in toxoplasmosis and related parasitic diseases. -
NLRP3 Inhibitor
NLRP3-IN-78 is a potent inhibitor of the NLRP3 inflammasome, demonstrating a 46.72% inhibition rate in GSDMD-induced pyroptosis at a concentration of 5 μM. This compound effectively binds to the NLRP3 protein, hindering GSDMD-NT oligomerization and cleavage while also suppressing upstream NF-κB signaling. NLRP3-IN-78 serves as a valuable tool for investigating anti-inflammatory mechanisms and the role of NLRP3 in various disease models. -
Contrast Medium
Perflubron (Perfluorooctyl bromide) serves as a contrast medium for magnetic resonance imaging (MRI) and sonography. It exhibits the ability to inhibit chemokine expression and NF-κB activation, contributing to its anti-inflammatory, antiviral, and cytoprotective effects. Perflubron can be emulsified with egg phospholipids, facilitating its use in various imaging applications, and is characterized by notably rapid excretion properties, making it a valuable reagent in clinical and research settings. -
EPAC2 Inhibitor
MAY0132 is a potent and selective inhibitor of the EPAC2 pathway, exhibiting an IC50 of 0.4 μM. This compound significantly impedes the replication of human metapneumovirus (HMPV), adenovirus (AdV), and respiratory syncytial virus (RSV), while also decreasing cytokine and chemokine production induced by viral infections. Furthermore, MAY0132 inhibits NF-κB activation, underscoring its utility in research focused on antiviral mechanisms and respiratory virus pathogenesis. -
STING Activator
diABZI-4 is a potent STING activator that enhances the host immune response through immunostimulatory activity. By promoting STING oligomerization, diABZI-4 activates the TBK1-IRF3 and NF-κB signaling pathways, leading to increased production of type I/III interferons and proinflammatory cytokines. This reagent demonstrates broad-spectrum antiviral efficacy against various viruses, including influenza A, SARS-CoV-2, and herpes simplex virus. diABZI-4 is instrumental in research related to COVID-19, respiratory viral infections, and the associated immunopathological mechanisms, making it a valuable tool for studying viral pathogenesis and developing therapeutic strategies. -
Stable Isotope
Myristic acid-13C2 is a stable isotope-labeled variant of myristic acid, a saturated 14-carbon fatty acid commonly found in various animal and plant fats, including milk fat and coconut oil. This compound exhibits anti-inflammatory effects primarily through the NF-κB signaling pathway and demonstrates antibacterial, anti-inflammatory, and analgesic activities. Myristic acid-13C2 is valuable in metabolic studies, allowing researchers to investigate fatty acid metabolism and functionality in biochemical pathways. -
IFN-γ Promoter Enhancer
Centaurein is a flavonoid that functions as an enhancer of the IFN-γ promoter, significantly up-regulating the activity of NFAT and NF-κB enhancers. It has been shown to increase IFN-γ expression in T and NK cells, resulting in elevated serum IFN-γ levels in murine models. Additionally, Centaurein induces complete relaxation of contractions in intact rat aortic rings and demonstrates protective effects against Listeria infection in mice, making it a valuable tool for research in immunology and vascular biology. -
HIV-1 Latency-Reversing Agent
Ciapavir is an HIV-1 latency-reversing agent that targets cIAP1, facilitating the degradation of this inhibitor and subsequently activating the non-canonical NF-κB pathway. This compound effectively reverses latent HIV-1 reservoirs both in vitro and in vivo, while minimizing systemic T cell activation and broad cytokine release. Ciapavir is a valuable tool for research into HIV-1 infection and the mechanisms of latency reversal. -
Endogenous Metabolite
Nervonic acid is a monounsaturated fatty acid recognized for its role as an endogenous metabolite. This compound demonstrates anti-inflammatory activity primarily through the inhibition of NF-κB signaling pathways. Its properties make it a valuable tool for investigating neurodegenerative diseases and related pathologies. -
Antioxidant Agent
Chrysoeriol is a natural flavonoid known for its antioxidant properties. This compound exhibits significant anti-inflammatory activity by inhibiting critical signaling pathways, including JAK2/STAT3, IκB/p65, and NF-κB. Due to its robust biological activities, chrysoeriol is valuable in research applications focused on inflammation and oxidative stress-related conditions. -
Endogenous Metabolite
Stachydrine is an endogenous metabolite that primarily functions in promoting blood circulation and alleviating blood stasis, particularly noted in the traditional Chinese herb Leonurus heterophyllus. This compound has been shown to inhibit the NF-κB signaling pathway, suggesting its potential role in modulating inflammatory processes. Stachydrine is valuable for research applications focused on cardiovascular health and inflammation. -
Vitamin E
γ-Tocotrienol is an active form of vitamin E that primarily targets the signaling pathway of NF-κB and P-glycoprotein (P-gp). It demonstrates significant biological activity by reversing multidrug resistance (MDR) in breast cancer cells, enhancing the efficacy of chemotherapeutic agents. Additionally, γ-tocotrienol serves as a radioprotective agent, effectively mitigating bone marrow radiation damage associated with targeted radionuclide treatments. Research applications include cancer therapy and protection against radiation-induced injury. -
ACAT Inhibitor
ACAT-IN-7 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. This compound effectively inhibits ACAT activity, resulting in altered lipid metabolism and subsequent reduction in cholesterol esterification. ACAT-IN-7 is of particular interest in research exploring its potential role in inflammatory processes, as it inhibits NF-κB mediated transcription, which is crucial for various cellular responses. -
ACAT Inhibitor
ACAT-IN-2 is a selective inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT). This compound effectively inhibits the NF-κB mediated transcriptional process, making it a valuable tool for research in cholesterol metabolism and inflammatory pathways. ACAT-IN-2 is primarily utilized in studies investigating dyslipidemia and its associated diseases, contributing to a deeper understanding of lipid regulation and associated pathophysiology. -
ACAT Inhibitor
ACAT-IN-10 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor that provides valuable insights into lipid metabolism. This compound is particularly useful in studying the regulation of cholesterol esters and their implications in various diseases, including atherosclerosis and metabolic disorders. Additionally, ACAT-IN-10 exhibits weak inhibition of NF-κB-mediated transcription, making it a potential tool for investigating inflammatory pathways. -
ACAT Inhibitor
ACAT-IN-4 hydrochloride is a selective acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. It disrupts cholesterol esterification, leading to a reduction in lipid accumulation in cells. This compound has significant implications for research in atherosclerosis, inflammation, and lipid metabolism, particularly through its ability to inhibit NF-κB mediated transcription. -
ACAT Inhibitor
ACAT-IN-9 is a selective acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor that effectively disrupts the synthesis of cholesteryl esters. By inhibiting ACAT activity, ACAT-IN-9 also attenuates NF-κB mediated transcription, which plays a critical role in inflammation and immune responses. This compound is utilized in research focusing on lipid metabolism, cardiovascular diseases, and inflammation pathways. -
ACAT Inhibitor
ACAT-IN-4 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor that effectively impedes ACAT activity. This compound has been shown to inhibit NF-κB mediated transcription, making it a valuable tool for studying cholesterol metabolism and inflammatory responses. ACAT-IN-4 is suitable for research applications focusing on lipid regulation, atherosclerosis, and other related cardiovascular conditions. -
ACAT Inhibitor
ACAT-IN-10 dihydrochloride is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. This compound exhibits weak inhibition of NF-κB mediated transcription, highlighting its potential role in modulating inflammatory processes. It is primarily utilized in research focused on lipid metabolism and its implications in various diseases, including atherosclerosis and metabolic disorders. ACAT-IN-10 dihydrochloride serves as a valuable tool for investigating the biochemical pathways regulated by ACAT activity. -
ACAT Inhibitor
ACAT-IN-6 is a potent acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. This compound effectively inhibits NF-κB mediated transcription, making it a valuable tool for studying lipid metabolism and inflammatory pathways. ACAT-IN-6 is useful in research applications focused on cholesterol homeostasis and related diseases. -
ACAT Inhibitor
ACAT-IN-3 is an inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT), targeting the cholesterol esterification pathway. This compound effectively inhibits NF-κB-mediated transcription, making it a valuable tool in studying pathways associated with inflammation and lipid metabolism. Its application in research may help elucidate the role of ACAT in various disease models, particularly those related to atherosclerosis and other metabolic disorders. -
ACAT Inhibitor
ACAT-IN-5 is a selective inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT), a key enzyme involved in cholesterol metabolism. By inhibiting ACAT activity, ACAT-IN-5 has been shown to modulate NF-κB mediated transcription, thereby influencing inflammatory pathways and lipid metabolism. This reagent is vital for research applications exploring cholesterol homeostasis, atherosclerosis, and related metabolic disorders. -
Anti-neuroinflammatory Agent
SB26019 is a potent anti-neuroinflammatory agent that primarily targets NF-κB activation. It functions by promoting the formation of monomeric α-tubulin, which in turn inhibits the translocation of the p65 subunit of NF-κB. This mechanism underscores its potential application in neuroscience research, particularly in studies related to neuroinflammation and associated disorders. -
MyD88 Inhibitor
T6167923 is a selective inhibitor of MyD88-dependent signaling pathways, targeting the Toll/IL-1 receptor (TIR) domain of MyD88 to disrupt its homodimeric formation. This compound effectively inhibits NF-κB-mediated Staphylococcus enterotoxin AP (SEAP) activity, demonstrating notable anti-inflammatory effects with IC50 values of 2.7 μM for IFN-γ, 2.9 μM for IL-1β, 2.66 μM for IL-6, and 2.66 μM for TNF-α. T6167923 serves as a valuable tool in studying the role of MyD88 signaling in inflammatory responses and therapeutic interventions. -
Myd88 Inhibitor
MyD88-IN-1 is a potent inhibitor of MyD88, targeting the interaction between TLR4 and MyD88. By suppressing the NF-κB signaling pathway, MyD88-IN-1 demonstrates significant biological activity relevant to cancer and inflammatory research. This compound serves as a valuable tool for elucidating the role of MyD88 in various disease processes and therapeutic interventions. -
Quinazoline alkaloid
Dehydroevodiamine is a key bioactive quinazoline alkaloid derived from Evodiae Fructus, primarily known for its antiarrhythmic properties demonstrated in guinea pig ventricular myocytes. This compound effectively inhibits the expression of lipopolysaccharide (LPS)-induced inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), and nuclear factor-kappa B (NF-κB) in murine macrophage cells. Its diverse biological activities make it a valuable reagent for research focused on cardiovascular function and inflammatory responses. -
Syk Inhibitor
DBMB is a selective inhibitor of spleen tyrosine kinase (Syk) that effectively attenuates Syk kinase activity. Its mechanism of action involves the suppression of NF-κB signaling, leading to a decrease in the production of key inflammatory mediators, including nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB is suitable for investigations focused on inflammatory diseases and elucidating the role of Syk in immune response pathways. -
iNOS Inhibitor
Asperuloside is an iridoid compound derived from Hedyotis diffusa, primarily known for its role as an inducible nitric oxide synthase (iNOS) inhibitor. This compound exhibits notable anti-inflammatory properties by suppressing the NF-κB and MAPK signaling pathways. Asperuloside is valuable in studying inflammatory processes and developing therapeutic strategies for related diseases. -
NF-κB Inhibitor
Neocryptotanshinone is a potent NF-κB inhibitor derived from Salvia miltiorrhiza. This compound effectively suppresses lipopolysaccharide-induced inflammation by targeting and inhibiting the NF-κB and iNOS signaling pathways. It shows promise in research applications focused on inflammatory diseases and provides valuable insights into the mechanisms of immune response modulation. -
iNOS/Nf-Κb Inhibitor
Hymenoxin is a dual inhibitor of inducible nitric oxide synthase (iNOS) and nuclear factor kappa B (NF-κB), exhibiting IC50 values of 42.7 μM and 85.5 μM, respectively. This compound demonstrates the capacity to reduce oxidative stress by 16% at a concentration of 125 μg/mL. Hymenoxin is primarily utilized in research focused on inflammatory responses and related signaling pathways. Its inhibitory effects on key regulators make it valuable for studies investigating the roles of iNOS and NF-κB in various disease models. -
Anti-apoptotic Agent
Bacoside A is an anti-apoptotic triterpenoid saponin derived from Bacopa monnieri, known for its ability to penetrate the blood-brain barrier. It exhibits significant antioxidant, anti-inflammatory, and neuroprotective properties by modulating the activities of ATPases, AChE, CaMK2A, and iNOS. Bacoside A helps maintain ion balance, scavenges reactive oxygen species, and regulates NF-κB and apoptosis-related proteins, thereby protecting nerve cells from stress-induced damage and exerting non-apoptotic cytotoxicity against glioblastoma cells. Its applications extend to research in neurological disorders, including Parkinson's disease and glioblastoma multiforme. -
Anti-Inflammatory Agent
PPM-18 (NSC 73233) is a potent anti-inflammatory agent that inhibits nitric oxide synthase (iNOS) expression by preventing NF-κB from binding to its promoter. This compound has demonstrated the ability to induce autophagy and apoptosis in bladder cancer cells, mediated through reactive oxygen species (ROS) and AMP-activated protein kinase (AMPK) signaling pathways. PPM-18 is valuable for researchers studying inflammation and cancer therapeutics. -
NOS Inhibitor
SDMA (p-hydroxyazobenzene-p′-sulfonate) is a potent endogenous inhibitor of nitric oxide synthase (NOS), making it a valuable tool for studying NOS-related pathways. This compound has been shown to activate NF-κB, leading to increased expression of pro-inflammatory cytokines such as IL-6 and TNF-α. Additionally, SDMA demonstrates stability in serum and plasma, allowing its use as a biomarker for assessing hepatic and renal dysfunction in various research applications.
